Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC)
BPC-157 Dosing Healthcare providers commonly prescribe BPC-157 at 250 to 500 micrograms per day
You can find more details in our Best Practices for Peptide Storage & Handling and Peptide Storage Stability Guidelines
A20-014, A22-082, A24-254, A28-092, and A30-143)
Sit down
US$ 29.64
US$ 20.14
US$ 20.26
US$ 24.16
US$ 27.40
US$ 29.78
